We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed’s Substack by Patients Capital Management. In ...

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Fintel reports that on July 14, 2025, HC Wainwright & Co. downgraded their outlook for Verona Pharma plc - Depositary Receipt ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck ( NYSE: MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma ( NASDAQ: VRNA ), a biotech firm ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

U.S.-listed shares of Verona Pharma ( VRNA) soared to an all-time high Wednesday after Merck ( MRK) agreed to pay about $10 ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma giant’s pipeline and portfolio of cardio-pulmonary disease treatments.

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...